Background Point-of-care (POC) hepatitis C virus (HCV) RNA nucleic acid test viral load
assays are being used increasingly as an alternative to centralised, laboratory-based …

Psoriasis is a chronic, autoimmune, and non-communicable skin disease with a worldwide
prevalence rate of 2–3%, creating an economic burden on global health. Some significant …

Background Many people who have a positive hepatitis C virus (HCV) antibody (Ab) test
never receive a confirmatory HCV RNA viral load (VL) test. Reflex VL testing may help …

Objectives To assess progress in Australia toward the 2030 WHO hepatitis C elimination
targets two years after the introduction of highly effective direct‐acting antiviral (DAA) …

Despite the heavy disease burden posed by hepatitis B, around 90% of people living with
hepatitis B are not diagnosed globally. Many of the affected populations still have limited or …

New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV)
infection. HCV elimination is a global goal that will be difficult to achieve using the traditional …

There have been major strides towards the World Health Organization goal to eliminate
hepatitis C virus (HCV) infection as a global public health threat. The availability of simple …

Background With the advent of low‐cost generic direct‐acting antivirals (DAA), hepatitis C
(HCV) elimination is now achievable even in low‐/middle‐income settings. We assessed the …

Australia was one of the first countries with unrestricted access to government subsidized
direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study …

Abstract Point‐of‐care (POC) diagnostics overcome barriers to conventional hepatitis C
(HCV) testing in people who inject drugs. This study assessed impact on hepatitis C …